Addressing the opioid epidemic - Opportunities in the postmarketing setting

New England Journal of Medicine

Volumn 376, Issue 16, 2017, Pages 1502-1504

  Psaty, Bruce M ^a,b,c   Merrill, Joseph O ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NARCOTIC ANALGESIC AGENT;

ANALGESIA; CHRONIC PAIN; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EPIDEMIC; HUMAN; OPIATE ADDICTION; PATIENT CARE; PRESCRIPTION; PUBLIC HEALTH; REVIEW; RISK BENEFIT ANALYSIS; DIRECT-TO-CONSUMER ADVERTIZING; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; LEGISLATION AND JURISPRUDENCE; OPIOID-RELATED DISORDERS; POSTMARKETING SURVEILLANCE; UNITED STATES;

ANALGESICS, OPIOID; DIRECT-TO-CONSUMER ADVERTISING; EPIDEMICS; GOVERNMENT REGULATION; HUMANS; OPIOID-RELATED DISORDERS; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85018477823     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1614972     Document Type: Review

References (5)

1. Califf RM, Woodcock J, Ostroff S. A proactive response to prescription opioid abuse. N Engl J Med 2016; 374: 1480-5.
2. Ballantyne JC, Sullivan MD. Intensity of chronic pain - the wrong metric? N Engl J Med 2015; 373: 2098-9.
3. Van Zee A. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am J Public Health 2009; 99: 221-7.
4. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015; 162: 276-86.
5. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016; 375: 2519-29.